Compile Data Set for Download or QSAR
Report error Found 677 Enz. Inhib. hit(s) with all data for entry = 592
TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280654(US10030020, Example 199 | US10781211, Example 199)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280655(US10030020, Example 200 | US10781211, Example 200)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280487(US10030020, Example 32 | US10781211, Example 32)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280656(US10030020, Example 201)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280657(US10030020, Example 202)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280658(US10030020, Example 203)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280488(US10030020, Example 33 | US10781211, Example 33)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280659(US10030020, Example 204)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280660(US10030020, Example 205 | US10781211, Example 205)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280661(US10030020, Example 206 | US10781211, Example 206)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280484(US10030020, Example 29 | US10781211, Example 29)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280652(US10030020, Example 197)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280485(US10030020, Example 30 | US10781211, Example 30)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280653(US10030020, Example 198 | US10781211, Example 198)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280654(US10030020, Example 199 | US10781211, Example 199)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280486(US10030020, Example 31 | US10781211, Example 31)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280670(US10030020, Example 219)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280492(US10030020, Example 37 | US10781211, Example 37)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280671(US10030020, Example 221)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280672(BDBM280720 | US10030020, Example 222)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280673(US10030020, Example 223 | US10781211, Example 223)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280493(US10030020, Example 38 | US10781211, Example 38)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280674(US10030020, Example 225 | US10781211, Example 225)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280675(US10030020, Example 226)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280676(US10030020, Example 228)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280494(US10030020, Example 39 | US10781211, Example 39)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280677(US10030020, Example 229)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280489(US10030020, Example 34 | US10781211, Example 34)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280662(US10030020, Example 209 | US10781211, Example 209)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280663(US10030020, Example 210 | US10781211, Example 210)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280664(US10030020, Example 211)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280490(US10030020, Example 35 | US10781211, Example 204)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280665(US10030020, Example 214 | US10781211, Example 214)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280574(BDBM280666 | US10030020, Example 119 | US10781211,...)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280667(US10030020, Example 216)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280491(US10030020, Example 36 | US10781211, Example 203)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280668(US10030020, Example 217 | US10781211, Example 217)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280669(US10030020, Example 218 | US10781211, Example 218)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280497(US10030020, Example 42 | US10781211, Example 42)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280498(US10030020, Example 43 | US10781211, Example 43)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280686(US10030020, Example 238)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280687(US10030020, Example 239)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280688(US10030020, Example 240 | US10781211, Example 240)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280689(US10030020, Example 241)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280678(US10030020, Example 230 | US10781211, Example 230)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280679(US10030020, Example 231)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Mouse)
Abide Therapeutics

US Patent
LigandPNGBDBM280495(US10030020, Example 40 | US10781211, Example 40)
Affinity DataIC50: 100nMAssay Description:Proteomes (mouse brain membrane fraction or cell lysates) (50 μL, 1.0 mg/mL total protein concentration) were preincubated with varying concentr...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280680(US10030020, Example 232)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280681(US10030020, Example 233)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

TargetMonoglyceride lipase(Human)
Abide Therapeutics

US Patent
LigandPNGBDBM280682(US10030020, Example 234)
Affinity DataIC50: 100nMT: 2°CAssay Description:Proteomes (human prefrontal cortex or cell membrane fractions) (50 μL, 1.0-2.0 mg/mL total protein concentration) were preincubated with varying...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/31/2018
Entry Details
US Patent

Displayed 1 to 50 (of 677 total ) | Next | Last >>
Jump to: